RNAi modulation of the BCR-ABL fusion gene and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7994307
APP PUB NO 20100234446A1
SERIAL NO

12510128

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ALNYLAM PHARMACEUTICALS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hadwiger, Philipp Altenkunstadt, DE 65 2515
Van, Der Kuip Heiko Ammerbuch, DE 5 7
Vornlocher, Hans-Peter Bayreuth, DE 95 2072

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation